$25.38
+1.23 (+5.09%)
Open$25.81
Previous Close$24.15
Day High$25.97
Day Low$23.92
52W High$43.85
52W Low$7.15
Volume—
Avg Volume319.7K
Market Cap360.08M
P/E Ratio—
EPS$-16.35
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-63.7% upside
Current
$25.38
$25.38
Target
$9.21
$9.21
$5.69
$9.21 avg
$10.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 171.10M | 149.07M | 26.00M |
| Net Income | -319,024,472 | -250,149,873 | 1.01M |
| Profit Margin | -186.5% | -177.1% | 3.9% |
| EBITDA | -252,172,128 | -208,715,387 | 1.64M |
| Free Cash Flow | — | — | 646.8K |
| Rev Growth | +14.8% | +14.8% | +22.0% |
| Debt/Equity | 4.05 | 4.05 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |